Pharmacokinetics of atracurium and its metabolites.
The pharmacokinetic profile of atracurium was studied in normal patients and in patients with renal failure, renal-hepatic failure, or hepatic disease. Its short elimination half-life was not significantly altered by renal failure, but in patients with severe liver disease elimination of its metabolites was prolonged, necessitating care during long-term i.v. infusions in patients with hepatic dysfunction.
D001279:Atracurium; D002908:Chronic Disease; D006207:Half-Life; D006801:Humans; D007546:Isoquinolines / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D009466:Neuromuscular Blocking Agents / Q000378:metabolism*
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D001279:Atracurium; C001522:laudanosine